von Willebrand Factor, Soluble P-Selectin, Tissue Plasminogen Activator and Plasminogen Activator Inhibitor in Atherosclerosis
A D Blann
1
The Department of Surgery, University Hospital of South Manchester, Manchester, UK
,
M Dobrotova
2
The Department of Haematology and Blood Transfusion, Jessenius Medical Faculty, Comenius University, Martin’s Faculty Hospital, Martin, Slovak Republic
,
P Kubisz
2
The Department of Haematology and Blood Transfusion, Jessenius Medical Faculty, Comenius University, Martin’s Faculty Hospital, Martin, Slovak Republic
,
C N McCollum
1
The Department of Surgery, University Hospital of South Manchester, Manchester, UK
Tissue plasminogen activator antigen (tPA), plasminogen activator inhibitor antigen (PAI-1), soluble P-selectin and von Willebrand factor antigen (vWf) were measured by ELISA in 41 patients with peripheral vascular disease (PVD), 41 with ischaemic heart disease (IHD) and in 46 age and sex matched asymptomatic controls. Increased vWf was found in patients with IHD (p = 0.0002) and in patients with PVD (p = 0.0011) relative to the controls but levels did not differ between the two patients groups. Raised tPA found in both PVD (p = 0.0006) and IHD (p = 0.0061) compared to the controls also failed to differentiate the two groups of patients. Soluble P-selectin was also raised in both groups (p = 0.003 in IHD and p = 0.0102 in PVD) with no difference between the groups. There were no differences in levels of PAI-1 between the groups. In the subjects taken as a whole, there were significant Spearman’s correlations between tPA and vWf (r = 0.37, p <0.001), tPA and triglycerides (r = 0.38, p <0.001), tPA and P-selectin (r = 0.19, p = 0.032), vWf and age (r = 0.25, p = 0.005) and inversely between vWf and HDL (r = -0.25, p = 0.006). These data support the concept that increased levels of tPA may be important in atherosclerosis, and indicate that soluble P-selectin may be useful in further analysis of the role of platelets and the endothelial cell in this disease.
References
1
Borsum T.
Biochemical properties of vascular endothelial cells. Virchows Archiv B Cell Pathol 1991; 60: 279-286
5
Nilsson TK,
Boman K,
Bjerle P,
Hallamns G,
Hellsten G.
von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Int Med 1994; 235: 419-423
6
Hamsten A,
Faire U de,
Walldius G,
Dahlen G,
Szamosi A,
Landou C,
Blomback M,
Wiman B.
Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-8
15
Mustard JF,
Packham MA.
The role of blood and platelets in atherosclerosis and the complications of atherosclerosis. Thromb Diathes Haemorrh 1975; 33: 444-56
20
Oseroff A,
Krishnamurti C,
Hassett A,
Tang D,
Alving B.
Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989; 113: 88-93
21
Speiser W,
Speiser P,
Minar E,
Kominger C,
Neissner H,
Huber K,
Schemthaner G,
Ehringer H,
Lechner K.
Activation of coagulation and fibrinolysis in patients with arteriosclerosis: Relation to localisation of vessel disease and risk factors. Thrombosis Res 1990; 59: 77-88
23
Munkvad S,
Jespersen J,
ram J,
Kluft C.
Interrelationship between coagulant activity and tissue type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium J Int Med 1990; 228: 361-366
24
Cortellaro M,
Cofrancesco E,
Boschetti C,
Mussoni L,
Donati MB,
Cardillo M,
Catalano M,
Gabrielli L,
Lombardi B,
Specchia G.
et al.
Increased fibrin turnover and high PAI-1 activity as predictors of ischaemic events in atherosclerosis patients. A case control study The PLAT group Arteriosclerosis Thromb 1993; 13: 1412-1417
25
Kunzendorf U,
Notter M,
Hock H,
Distler A,
Diamantstein T,
Walz G.
T cells bind to the endothelial adhesion molecule GMP-140 (P-selectin). Transplantation 1993; 56: 1213-1217
28
Wong CS,
Gamble JR,
Skinner MP,
Lucas CM,
Berndt MC,
Vadas MA.
Adhesion protein GMP140 inhibits superoxide anion release by human neutrophils. Proc Natl Acad Sci USA 1991; 88: 2397-2401
31
Takahashi H,
Ito S,
Hanano M,
Wada K,
Niwano H,
Seki Y,
Shibata A.
Circulatingthrombodulin as a novel endothelial cell marker: Comparison of its behaviour with von Willebrand factor and tissue type plasminogen activator. Am J Haem 1992; 41: 32-39
33
Lupu F,
Bergonzelli GE,
Heim DA,
Cousin E,
Genton CY,
Bachmann F,
Kruithof EK O.
Localisation and production of plasminogen activator inhibitor-1 in human healthy and atherosclerosis arteries. Arteriosclerosis Thromb 1993; 13: 1090-1100
34
Wang DL,
Pan YT,
Wang JJ,
Cheng CH,
Liu CY.
Demonstration of a functionally active tPA-like plasminogen activator in human platelets. Thromb Haemost 1994; 71: 493-498
35
Torr-Brown SR,
Sobel BE.
Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thrombosis Res 1993; 413-421
37
Collins PW,
Macey MG,
Cahill MR,
Newland AC.
von Willebrand factor release and P-selectin expression is stimulated by thrombin and trypsin but not IL-1 in cultured human endothelial cells. Thromb Haemost 1993; 70: 346-350
39
Gershlick AH.
Are there markers of the blood-vessel wall interaction and of thrombus formation that can be used clinically. Circulation 1990; 81 Suppl (Suppl. 01) I-28-I-34
